Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Abstract Background Systemic bevacizumab is a novel targeted anti-angiogenic therapy for high-output cardiac failure (HOCF) in hereditary hemorrhagic telangiectasia (HHT) but published data is limited. This survey-based study measured physician-reported safety, effectiveness and current treatment pr...

Full description

Bibliographic Details
Main Authors: Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy, Vivek N. Iyer
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Hereditary hemorrhagic telangiectasia
Osler-weber-Rendu
HHT
Bevacizumab
High-output cardiac failure
Heart failure
Online Access:http://link.springer.com/article/10.1186/s13023-019-1239-6

Internet

http://link.springer.com/article/10.1186/s13023-019-1239-6

Similar Items